AIVITA Advances Phase 2 Clinical Trial for Ovarian Cancer Vaccine

AIVITA Advances Phase 2 Clinical Trial for Ovarian Cancer Vaccine
AIVITA Biomedical has begun to randomize patients for a Phase 2 clinical trial assessing its cell-based immunotherapy for the treatment of newly-diagnosed advanced ovarian cancer. Currently recruiting participants at Hoag Memorial Hospital Presbyterian in California, the study is expected to enroll 99 patients who will receive AIVITA’s patient-specific ovarian cancer vaccine or a placebo. AIVITA’s immunotherapy uses a patient’s

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *